http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101193043-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| filingDate | 2007-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101193043-B1 |
| titleOfInvention | Monoclonal Antibody Against Soluble Type L0v1 |
| abstract | Monoclonal antibodies that specifically recognize human soluble LOX-1, in particular monoclonal antibodies with dissociation constants (Kd) with human soluble LOX-1, are 1 × 10 −9 M or less. The monoclonal antibody is produced from a hybridoma (hybridoma) prepared by a method comprising the steps of: 1) immunizing a human LOX-1 extracellular domain derived from prokaryotic cells to animals other than humans; 2) recovering the cells producing the antibody from the animal of step 1); 3) fusing the cells producing the antibody with myeloma cells; 4) selecting hybridomas from the fusion cells obtained in step 3), which produce monoclonal antibodies that react with human LOX-1 extracellular domains; And 5) selecting hybridomas that produce a monoclonal antibody that reacts with the human LOX-1 extracellular domain derived from eukaryotic cells from the hybridomas selected in step 4). |
| priorityDate | 2006-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 400.